Advertisement

Advertisement

32nd EORTC-NCI-AACR Symposium

Solid Tumors

Genetic Variants Linked to Bevacizumab-Induced Adverse Effects

Two common genetic variants appear to be linked to toxicity induced by bevacizumab, researchers reported at the 32nd European Organisation for Research and Treatment of Cancer (EORTC)–National Cancer ...

Immunotherapy
Supportive Care
Genomics/Genetics

Study Identifies Genetic Variants Linked to Bevacizumab-Induced Adverse Events

Researchers have found two common genetic variants that may be used to predict whether patients with cancer may have severe adverse events when treated with the anti-VEGF monoclonal antibody bevacizum...

Solid Tumors

Is a High-Dose Intermittent Sunitinib Regimen for Advanced Solid Tumors Linked to Improved Survival?

A strategy for giving intermittent, high doses of the tyrosine kinase inhibitor sunitinib seemed to be well tolerated by patients with advanced cancer and increased drug concentrations in solid tumors...

Immunotherapy

Effect of Angiotensin II Inhibition on Response to Immunotherapy

Researchers have found that a class of commonly used heart drugs may also improve patients’ responses to PD-L1 inhibitors, according to preliminary findings presented by Strauss et al at the 32th EORT...

Genomics/Genetics

Next-Generation BRAF Inhibitor Shows Activity in Phase I/II Trial

A new drug designed to treat cancers in patients with an altered BRAF gene showed activity and had a favorable safety profile in an early-phase trial. These findings were presented by Janku et al at t...

Genomics/Genetics

Targeted Inhibitor of Mutant KRAS Gene Shows Activity in Early Trial

Adagrasib (MRTX849), a novel agent that targets a mutated form of the KRAS gene—the most commonly altered oncogene in human cancers, and one long considered “undruggable”—caused tumor shrinkage in mos...

Advertisement

Advertisement



Advertisement